Investing.com - Prestige Consumer Health (NYSE: PBH) reported second quarter EPS of $1.09, $0.01 better than the analyst estimate of $1.08. Revenue for the quarter came in at $283.8M versus the consensus estimate of $282.17M.
Guidance
Prestige Consumer Health sees FY 2025 EPS of $4.40-$4.46 versus the analyst consensus of $4.42.
Prestige Consumer Health sees FY 2025 revenue of $1.13B-$1.14B versus the analyst consensus of $1.13B.
Prestige Consumer Health's stock price closed at $77.64. It is up 17.19% in the last 3 months and up 36.74% in the last 12 months.
Prestige Consumer Health saw 0 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See Prestige Consumer Health's stock price’s past reactions to earnings here.
According to InvestingPro, Prestige Consumer Health's Financial Health score is "great performance".
Check out Prestige Consumer Health's recent earnings performance, and Prestige Consumer Health's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar